Background
Methods
Patient background
To calculate smoking pack-years: Divide the number of cigarettes smoked per day by 20 (the number of cigarettes in a pack) Then multiply by the number of years smoked | |
ex. 1 | (70 cigarettes/day ÷ 20 cigarettes/pack) × 10 years = 35 pack-years |
ex. 2 | (35 cigarettes/day ÷ 20 cigarettes/pack) × 20 years = 35 pack-years |
ex. 3 | (20 cigarettes/day ÷ 20 cigarettes/pack) × 20 years = 20 pack-years |
Histopathological evaluation of TILs density
Statistical analysis
Ethics statement
Results
Clinicopathological features
Parameters (n = 149) | Number of patients (%) |
---|---|
Age (years old) | 56 (24–75) |
Tumour size (mm) | 27.6 (10.2–98.0) |
Skin infiltration | |
Negative/positive | 134 (89.9%)/15 (10.1%) |
Lymph node metastasis | |
N0/N1/N2/N3 | 51 (34.2%)/54 (36.2%)/29 (19.5%)/15 (10.1%) |
HER2 | |
Negative/positive | 87 (58.4%)/62 (41.6%) |
Ki67 | |
Negative/positive | 23 (15.4%)/126 (84.6%) |
ORR | |
Non-responders/responders | 11 (7.4%)/138 (92.6%) |
pCR | |
Negative/positive | 75 (50.3%)/74 (49.7%) |
Recurrence | |
Negative/positive | 123 (82.6%)/26 (17.4%) |
TILs | |
Low/high | 58 (38.9%)/91 (61.1%) |
Smoker | |
No/yes | 105 (70.5%)/44 (29.5%) |
Pack-years of smokers | 20 (2.5–135) |
Pack-years | |
Low/high | 106 (71.1%)/43 (28.9%) |
Parameters | Intrinsic subtype | p value | |
---|---|---|---|
HER2-enriched breast cancer (n = 62) | Triple-negative breast cancer (n = 87) | ||
Age (years old) | |||
≤ 56 | 26 (41.9%) | 49 (56.3%) | 0.085 |
> 56 | 36 (58.1%) | 38 (43.7%) | |
Tumour size (mm) | |||
≤ 27.6 | 30 (48.4%) | 45 (51.7%) | 0.690 |
> 27.6 | 32 (51.6%) | 42 (48.3%) | |
Skin infiltration | |||
Negative | 54 (87.1%) | 80 (92.0%) | 0.335 |
Positive | 8 (12.9%) | 7 (8.0%) | |
Lymph node status | |||
Negative | 25 (40.3%) | 26 (29.9%) | 0.188 |
Positive | 37 (59.7%) | 61 (70.1%) | |
Ki67 | |||
Negative | 14 (22.6%) | 9 (10.3%) | 0.042 |
Positive | 48 (77.4%) | 78 (89.7%) | |
ORR | |||
Non-responders | 1 (1.6%) | 10 (11.5%) | 0.023 |
Responders | 61 (98.4%) | 77 (88.5%) | |
pCR | |||
Negative | 26 (41.9%) | 49 (56.3%) | 0.085 |
Positive | 36 (58.1%) | 38 (43.7%) | |
Recurrence | |||
Negative | 55 (88.7%) | 68 (78.2%) | 0.096 |
Positive | 7 (11.3%) | 19 (21.8%) | |
TILs | |||
Low | 20 (32.3%) | 38 (43.7%) | 0.206 |
High | 42 (67.7%) | 49 (56.3%) | |
Pack-years | |||
Low | 40 (64.5%) | 66 (75.9%) | 0.134 |
High | 22 (35.5%) | 21 (24.1%) |
The associations of smoking with clinicopathological features, DFS, and OS
Parameters | Smoker | p value | Pack-years | p value | ||
---|---|---|---|---|---|---|
Yes (n = 44) | No (n = 105) | High (n = 43) | Low (n = 106) | |||
Age (years old) | ||||||
≤ 56 | 24 (54.5%) | 51 (48.6%) | 0.509 | 24 (55.8%) | 51 (48.1%) | 0.398 |
> 56 | 20 (45.5%) | 54 (51.4%) | 19 (44.2%) | 55 (51.9%) | ||
Tumour size (mm) | ||||||
≤ 27.6 | 25 (56.8%) | 50 (47.6%) | 0.309 | 25 (58.1%) | 50 (47.2%) | 0.228 |
> 27.6 | 19 (43.2%) | 55 (52.4%) | 18 (41.9%) | 56 (52.8%) | ||
Skin infiltration | ||||||
Negative | 40 (90.9%) | 94 (89.5%) | 0.799 | 40 (93.0%) | 94 (88.7%) | 0.428 |
Positive | 4 (9.1%) | 11 (10.5%) | 3 (7.0%) | 12 (11.3%) | ||
Lymph node status | ||||||
Negative | 18 (40.9%) | 33 (31.4%) | 0.269 | 18 (41.9%) | 33 (31.1%) | 0.214 |
Positive | 26 (59.1%) | 72 (68.6%) | 25 (58.1%) | 73 (68.9%) | ||
Ki67 | ||||||
Negative | 6 (13.6%) | 17 (16.2%) | 0.69 | 6 (14.0%) | 17 (16.0%) | 0.752 |
Positive | 38 (86.4%) | 88 (83.8%) | 37 (86.0%) | 89 (84.0%) | ||
Intrinsic subtype | ||||||
HER2-enriched | 22 (50.0%) | 40 (38.1%) | 0.181 | 22 (51.2%) | 40 (37.7%) | 0.134 |
Triple-negative | 22 (50.0%) | 65 (61.9%) | 21 (48.8%) | 66 (62.3%) | ||
ORR | ||||||
Non-responders | 3 (6.8%) | 8 (7.6%) | 0.866 | 3 (7.0%) | 8 (7.5%) | 0.905 |
Responders | 41 (93.2%) | 97 (92.4%) | 40 (93.0%) | 98 (92.5%) | ||
pCR | ||||||
Negative | 17 (38.6%) | 58 (55.2%) | 0.065 | 16 (37.2%) | 59 (55.7%) | 0.042 |
Positive | 27 (61.4%) | 47 (44.8%) | 27 (62.8%) | 47 (44.3%) | ||
Recurrence | ||||||
Negative | 40 (90.9%) | 83 (79.0%) | 0.083 | 39 (90.7%) | 84 (79.2%) | 0.096 |
Positive | 4 (9.1%) | 22 (21.0%) | 4 (9.3%) | 22 (20.8%) | ||
TILs | ||||||
Low | 13 (29.6%) | 45 (42.9%) | 0.075 | 12 (27.9%) | 46 (43.4%) | 0.043 |
High | 31 (70.5%) | 60 (57.1%) | 31 (72.1%) | 60 (56.6%) |
Parameters | Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | |
Disease-free survival | ||||||
Age at operation (year) | ||||||
≤ 56 | 0.614 | 0.269–1.335 | 0.220 | |||
> 56 | ||||||
Tumour size (mm) | ||||||
≤ 27.6 | 1.137 | 0.525–2.503 | 0.744 | |||
> 27.6 | ||||||
Skin infiltration | ||||||
Negative | 1.556 | 0.455–4.067 | 0.440 | |||
Positive | ||||||
Lymph node status | ||||||
Negative | 2.440 | 0.933–8.343 | 0.071 | 1.677 | 0.617–5.859 | 0.331 |
Positive | ||||||
Ki67 | ||||||
Negative | 0.394 | 0.180–0.926 | 0.034 | 0.770 | 0.321–1.942 | 0.568 |
Positive | ||||||
Intrinsic subtype | ||||||
HER2-enriched | 1.884 | 0.828–4.823 | 0.135 | |||
Triple-negative | ||||||
ORR | ||||||
Non-responders | 0.083 | 0.035–0.210 | < 0.001 | 0.154 | 0.059–0.426 | 0.001 |
Responders | ||||||
Pathological response | ||||||
Non-pCR | 0.203 | 0.068–0.499 | < 0.001 | 0.381 | 0.118–1.059 | 0.065 |
pCR | ||||||
TILs | ||||||
Low | 0.252 | 0.107–0.553 | 0.001 | 0.424 | 0.167–1.032 | 0.059 |
High | ||||||
Pack-years | ||||||
Low | 0.434 | 0.127–1.134 | 0.092 | 0.567 | 0.160–1.555 | 0.289 |
High | ||||||
Overall survival | ||||||
Age at operation (year) | ||||||
≤ 56 | 0.508 | 0.175–1.338 | 0.172 | |||
> 56 | ||||||
Tumour size (mm) | ||||||
≤ 27.6 | 1.123 | 0.429–2.993 | 0.811 | |||
> 27.6 | ||||||
Skin infiltration | ||||||
Negative | 1.939 | 0.446–5.977 | 0.335 | |||
Positive | ||||||
Lymph node status | ||||||
Negative | 2.778 | 0.781–17.657 | 0.125 | |||
Positive | ||||||
Ki67 | ||||||
Negative | 0.638 | 0.234–2.023 | 0.419 | |||
Positive | ||||||
Intrinsic subtype | ||||||
HER2-enriched | 1.610 | 0.597–5.060 | 0.357 | |||
Triple-negative | ||||||
ORR | ||||||
Non-responders | 0.077 | 0.026–0.238 | < 0.001 | 0.451 | 0.044–0.520 | 0.004 |
Responders | ||||||
Pathological response | ||||||
Non-pCR | 0.183 | 0.042–0.561 | 0.002 | 0.282 | 0.062–0.953 | 0.041 |
pCR | ||||||
TILs | ||||||
Low | 0.357 | 0.129–0.929 | 0.035 | 0.634 | 0.212–1.861 | 0.403 |
High | ||||||
Pack-years | ||||||
Low | 0.554 | 0.128–1.700 | 0.325 | |||
High |